gp100:209-217(210M)

gp100:209–217(210M) is a synthetic peptide cancer vaccine derived from amino acid residues 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen, with a methionine substitution at position 210. This modification increases its binding affinity to HLA-A2.1, enhancing T-cell stimulation and immunogenicity compared to the native peptide[1][2][5]. The vaccine is designed to stimulate cytotoxic T lymphocyte responses against melanoma cells expressing the gp100 antigen. It has been primarily investigated in combination with high-dose interleukin-2 (IL-2) for advanced or metastatic melanoma, where it showed improved immune response and some clinical benefit over IL-2 alone[3][4][5]. The primary mechanism involves presenting an HLA-A2-restricted epitope that activates CD8+ T cells targeting tumor cells[6][10].

Other names

gp100 cancer vaccinegp-100 cancer vaccinegp 100 cancer vaccinegp100 peptide vaccinegp-100 peptide vaccinegp 100 peptide vaccine